Quick Answer
Aligos Therapeutics, Inc. reported Total Assets of $88.53 million for the year ending 2025.
- Aligos Therapeutics, Inc. showed an increase of +26.3% in Total Assets from 2024 to 2025.
- This data is from Aligos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $92.18 million | Q1 2021: $234.54 million | Q2 2021: $211.88 million | Q3 2021: $263.07 million | Q1 2022: $210.47 million | Q2 2022: $182.52 million | Q3 2022: $164.07 million | Q1 2023: $121.74 million | Q2 2023: $106.13 million | Q3 2023: $85.85 million | Q1 2024: $127.90 million | Q2 2024: $108.81 million | Q3 2024: $88.43 million | Q1 2025: $150.70 million | Q2 2025: $134.71 million | Q3 2025: $109.76 million.
- Over the full 7 years of available data (2019 to 2025), Aligos Therapeutics, Inc.'s Total Assets has declined by 39.6%.
- Historical annual values: Fiscal year 2025: $88.53 million | Fiscal year 2024: $70.09 million | Fiscal year 2023: $151.53 million | Fiscal year 2022: $146.69 million | Fiscal year 2021: $235.37 million | Fiscal year 2020: $265.30 million | Fiscal year 2019: $146.52 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: